CYTORI THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. CYTORI THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 2.67 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 89.43% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||3.46||1.29|
|Net Income ($mil)||4.45||-11.83|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||23.84||12.76|
|Total Assets ($mil)||46.52||38.25|
|Total Debt ($mil)||16.21||26.84|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||71.14||54.88|
|Return on Assets||-70.17||-98.11|
|Return on Equity||-1525.61||-3145.68|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||150.96||79.54|
|Div / share||0.0||0.0|
|Book value / share||0.02||0.02|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1672570.0||4184989.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 20.13 indicates a significant premium versus the S&P 500 average of 2.67 and a premium versus the industry average of 18.95. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a premium to investment alternatives within the industry.
|CYTX NM||Peers 113.04||CYTX NM||Peers 39.68|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYTX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYTX's P/CF is negative making the measure meaningless.
|CYTX NM||Peers 21.43||CYTX NA||Peers 0.67|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CYTX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYTX 20.13||Peers 18.95||CYTX 25.50||Peers 35.03|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYTX is trading at a valuation on par with its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CYTX is expected to significantly trail its peers on the basis of its earnings growth rate.
|CYTX 4.24||Peers 345.34||CYTX 20.07||Peers 115.92|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYTX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYTX significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV